Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

[Castleman disease]

Autor: J, Sánchez de Toledo Sancho, J, Fàbrega Sabaté, C, Marhuenda Irastorza, X, Lucaya Layret, N, Torán Fuentes, L, Gros Subias, C, Sábado Alvarez

Publikováno v: Anales de pediatria (Barcelona, Spain : 2003). 63(1)

Castleman disease or angiofollicular hyperplasia is a rare disorder included in the group of lymphoproliferative disorders. This entity was originally described by Castleman in 1956. The etiology remains unknown but it is postulated to be a reactive

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::e211fec23739749e58b7726ef22c99c0
https://pubmed.ncbi.nlm.nih.gov/15989874

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Lenvatinib Plus Ifosfamide and Etoposide in Children and Young Adults With Relapsed Osteosarcoma: A Phase 2 Randomized Clinical Trial.

Autor: Gaspar N; Department of Oncology for Child and Adolescent, Gustave Roussy Cancer Campus, Villejuif, France., Hung GY; Department of Pediatrics, Taipei Veterans General Hospital, Taipei, Taiwan., Strauss SJ; London Sarcoma Service, University College London Hospital NHS Trust, London, United Kingdom., Campbell-Hewson Q; The Great North Children's Hospital, Royal Victoria Infirmary, Newcastle Upon Tyne, United Kingdom., Dela Cruz FS; Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, New York., Glade Bender JL; Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, New York., Koh KN; Division of Pediatric Hematology/Oncology, Department of Pediatrics, Asan Medical Center Children's Hospital, University of Ulsan College of Medicine, Seoul, Republic of Korea., Whittle SB; Department of Pediatrics, Texas Children's Cancer Center, Baylor College of Medicine, Houston., Chan GC; Department of Paediatrics and Adolescent Medicine, School of Clinical Medicine, The University of Hong Kong, Hong Kong Special Administrative Region, China., Gerber NU; Department of Oncology, University Children's Hospital Zürich, Zürich, Switzerland., Palmu S; Tampere Center for Child, Adolescent and Maternal Health Research, Faculty of Medicine and Health Technology, Tampere University and University Hospital, Tampere, Finland., Morgenstern DA; Division of Haematology/Oncology, Department of Paediatrics, Hospital for Sick Children and University of Toronto, Toronto, Ontario, Canada., Longhi A; Chemotherapy Service, Istituto Ortopedico Rizzoli, Istituto di Ricovero e Cura a Carattere Scientifico, Bologna, Italy., Baecklund F; Paediatric Oncology Unit, Karolinska University Hospital Solna, Stockholm, Sweden., Lee JA; Center for Pediatric Cancer, National Cancer Center, Goyang, Republic of Korea., Locatelli F; Department of Pediatric Hematology and Oncology, Istituto di Ricovero e Cura a Carattere Scientifico Ospedale Pediatrico Bambino Gesù, Catholic University of the Sacred Heart, Rome, Italy., Márquez Vega C; Department of Pediatric Oncology, Hospital Virgen del Rocío, Seville, Spain., Janeway KA; Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Harvard Medical School, Boston, Massachusetts., McCowage G; Cancer Centre for Children, The Children's Hospital at Westmead, Sydney, New South Wales, Australia., McCabe MG; Division of Cancer Sciences, The University of Manchester, Manchester, United Kingdom.; The Christie NHS Foundation Trust, Manchester, United Kingdom., Bidadi B; Clinical Research, Merck & Co Inc, Rahway, New Jersey., Huang J; Biostatistics, Eisai Inc, Nutley, New Jersey., McKenzie J; Oncology Business Group, Eisai Inc, Nutley, New Jersey., Okpara CE; Clinical Research, Eisai Ltd, Hatfield, United Kingdom., Bautista F; Hospital del Niño Jesús, Madrid, Spain.; Now with Princess Maxima Centrum for Pediatric Cancer, Utrecht, the Netherlands.

Publikováno v: JAMA oncology [JAMA Oncol] 2024 Oct 17. Date of Electronic Publication: 2024 Oct 17.